RU2737190C2 - Ингибиторы репликации вируса гриппа, способы их применения и использование - Google Patents

Ингибиторы репликации вируса гриппа, способы их применения и использование Download PDF

Info

Publication number
RU2737190C2
RU2737190C2 RU2018124993A RU2018124993A RU2737190C2 RU 2737190 C2 RU2737190 C2 RU 2737190C2 RU 2018124993 A RU2018124993 A RU 2018124993A RU 2018124993 A RU2018124993 A RU 2018124993A RU 2737190 C2 RU2737190 C2 RU 2737190C2
Authority
RU
Russia
Prior art keywords
mmol
ring
compound
independently
mixture
Prior art date
Application number
RU2018124993A
Other languages
English (en)
Russian (ru)
Other versions
RU2018124993A3 (https=
RU2018124993A (ru
Inventor
Инцзюнь ЧЖАН
Циньюнь ЖЭНЬ
Чанхуа ТАН
Сяохун ЛИНЬ
Цзюньцзюнь ИНЬ
Кай И
Original Assignee
Саншайн Лейк Фарма Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саншайн Лейк Фарма Ко., Лтд. filed Critical Саншайн Лейк Фарма Ко., Лтд.
Publication of RU2018124993A publication Critical patent/RU2018124993A/ru
Publication of RU2018124993A3 publication Critical patent/RU2018124993A3/ru
Application granted granted Critical
Publication of RU2737190C2 publication Critical patent/RU2737190C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018124993A 2015-12-09 2016-12-08 Ингибиторы репликации вируса гриппа, способы их применения и использование RU2737190C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510908329.2 2015-12-09
CN201510908329 2015-12-09
PCT/CN2016/109079 WO2017097234A1 (en) 2015-12-09 2016-12-08 Inhibitors of influenza virus replication, application methods and uses thereof

Publications (3)

Publication Number Publication Date
RU2018124993A RU2018124993A (ru) 2020-01-14
RU2018124993A3 RU2018124993A3 (https=) 2020-02-05
RU2737190C2 true RU2737190C2 (ru) 2020-11-25

Family

ID=59012608

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018124993A RU2737190C2 (ru) 2015-12-09 2016-12-08 Ингибиторы репликации вируса гриппа, способы их применения и использование

Country Status (9)

Country Link
US (2) US10717732B2 (https=)
EP (1) EP3362451B1 (https=)
JP (1) JP6952695B2 (https=)
KR (1) KR102671350B1 (https=)
CN (2) CN109748915B (https=)
AU (1) AU2016368317B2 (https=)
RU (1) RU2737190C2 (https=)
SG (1) SG11201804225PA (https=)
WO (1) WO2017097234A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109748915B (zh) * 2015-12-09 2021-03-26 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CN109071567B (zh) * 2016-05-19 2021-03-23 四川大学 抗流感小分子化合物及其制备方法和用途
CN107759571B (zh) 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CN109641868B (zh) 2016-08-30 2021-12-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
SG11201901894TA (en) 2016-09-05 2019-04-29 Guangdong Raynovent Biotech Co Ltd Anti-influenza virus pyrimidine derivatives
US10987354B2 (en) 2016-12-15 2021-04-27 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
WO2018200425A1 (en) * 2017-04-24 2018-11-01 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
CN109384783A (zh) * 2017-08-09 2019-02-26 银杏树药业(苏州)有限公司 新型杂环化合物及其作为抗流感病毒抑制剂的医药用途
WO2019155468A1 (en) * 2018-02-08 2019-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
JP7031002B2 (ja) * 2018-03-05 2022-03-07 広東衆生睿創生物科技有限公司 ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
CN114340614B (zh) * 2019-09-27 2024-01-16 广东东阳光药业股份有限公司 一种奥司他韦制剂
CN110967239B (zh) * 2020-01-02 2022-05-10 国家地质实验测试中心 一种金属铬溶解氧化方法
CN117362318A (zh) * 2020-07-10 2024-01-09 西藏海思科制药有限公司 Pb2抑制剂及其制备方法和用途
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US20250289826A1 (en) * 2022-04-29 2025-09-18 Tsinghua University Plpro protein inhibitor, and preparation method and application thereof
WO2026016541A1 (zh) * 2024-07-16 2026-01-22 武汉武药科技有限公司 一种新型抗病毒化合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148197A1 (en) * 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RU2010119561A (ru) * 2004-03-30 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Азаиндолы, полезные в качестве ингибиторов jак и других протеинкиназ
WO2013019828A1 (en) * 2011-08-01 2013-02-07 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2015073476A1 (en) * 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006840A (es) * 2010-12-16 2014-01-31 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
CN103492382A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CN103702998A (zh) * 2011-07-05 2014-04-02 沃泰克斯药物股份有限公司 生产氮杂吲哚类的方法和中间体
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
KR20160084465A (ko) 2013-11-13 2016-07-13 버텍스 파마슈티칼스 인코포레이티드 아자인돌 화합물의 제형
HRP20181272T1 (hr) 2013-11-13 2018-10-05 Vertex Pharmaceuticals Incorporated Postupci priprave inhibitora replikacije virusa influence
UA124609C2 (uk) 2014-08-08 2021-10-20 Янссен Саєнсиз Айрленд Юсі Індоли для застосування при інфекції, спричиненій вірусом грипу
HUE053595T2 (hu) 2014-09-08 2021-07-28 Janssen Sciences Ireland Unlimited Co Pirrolopirimidinek influenzavírus-fertõzésnél történõ alkalmazásra
CN109748915B (zh) * 2015-12-09 2021-03-26 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment, amelioration or prevention of influenza

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010119561A (ru) * 2004-03-30 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Азаиндолы, полезные в качестве ингибиторов jак и других протеинкиназ
WO2010148197A1 (en) * 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2013019828A1 (en) * 2011-08-01 2013-02-07 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2015073476A1 (en) * 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. BOYD et al., Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors, BIOORG. MED. CHEM. LETT., 2015, V.25, p. 1990-1994. *

Also Published As

Publication number Publication date
JP2018536681A (ja) 2018-12-13
KR102671350B1 (ko) 2024-05-30
JP6952695B2 (ja) 2021-10-20
CN109748915B (zh) 2021-03-26
US11225477B2 (en) 2022-01-18
US10717732B2 (en) 2020-07-21
RU2018124993A3 (https=) 2020-02-05
KR20180088466A (ko) 2018-08-03
US20180346463A1 (en) 2018-12-06
AU2016368317A1 (en) 2018-06-07
CA3005921A1 (en) 2017-06-15
CN109748915A (zh) 2019-05-14
CN106854205A (zh) 2017-06-16
EP3362451A1 (en) 2018-08-22
AU2016368317B2 (en) 2019-05-23
WO2017097234A1 (en) 2017-06-15
SG11201804225PA (en) 2018-06-28
RU2018124993A (ru) 2020-01-14
EP3362451A4 (en) 2019-07-03
HK1254668A1 (en) 2019-07-26
EP3362451B1 (en) 2023-04-12
CN106854205B (zh) 2019-07-09
US20200299294A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
RU2737190C2 (ru) Ингибиторы репликации вируса гриппа, способы их применения и использование
US10647693B2 (en) Inhibitors of influenza virus replication, application methods and uses thereof
JP7034162B2 (ja) インフルエンザウイルス複製の阻害剤及びその使用
US11098042B2 (en) Inhibitors of influenza virus replication and uses thereof
US10501444B2 (en) Inhibitors of influenza virus replication, application methods and uses thereof
US10927118B2 (en) Inhibitors of influenza virus replication and uses thereof
CN110117285A (zh) 流感病毒复制抑制剂及其用途
CA3005921C (en) Substituted-(pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin derivatives and use thereof as inhibitors of influenza virus replication
HK1254668B (en) Inhibitors of influenza virus replication, application methods and uses thereof
HK40011744A (en) Inhibitors of influenza virus replication and uses thereof
HK40011744B (en) Inhibitors of influenza virus replication and uses thereof
HK40002434A (en) Inhibitors of influenza virus replication, application methods and uses thereof